Leading North India ISP cites IP Infusion's superior open networking technology and lower costs as distinct competitive advantages
SANTA CLARA, Calif., April 5, 2023 – IP Infusion, a leading provider of open network software and solutions for wireline and mobile network operators, today announced that Netplus Broadband, North India's leading wireline internet service provider, has chosen IP Infusion's OcNOS® to strengthen and scale its network as the company expands broadband services to all its customers across the region. Netplus Broadband is the Internet arm of Fastway Transmissions Pvt Ltd.
Netplus is deploying OcNOS's Multiprotocol Label Switching (MPLS) and Ethernet VPN (EVPN) features to enhance network security, efficiency and transmission rates. The IP Infusion software, running on UfiSpace's open networking hardware platform, interoperates seamlessly with Netplus' legacy Nokia and Cisco routers, and also replaces ZTE. Distribution partner Antriksh Digital Solution supported the high-performance service solution. Netplus Broadband covers a wide portion of North India, with operations in eight states and 400+ cities to provide broadband, fixed-line and enterprise services.
"We are continually striving to provide the best possible internet service to our customers, who rely on us for secure, fast and economical connections," said Arshdeep Singh Mundi, Executive Director at Netplus. "Our research confirmed that IP Infusion's open networking OcNOS software not only boasts superior technology, but is highly cost-effective, easy to integrate and will strategically position us for further expansion."
"Netplus chose to integrate OcNOS for its demonstrated reliability, competitive pricing and the IP Infusion commitment to customer service," said Atsushi Ogata, CEO and President of IP Infusion. "We are confident they will find network disaggregation to be highly beneficial with many market attributes including lower CAPEX and OPEX and a shorter time to rolling out new services to their customers."
About Netplus Broadband
The ICT – (Information, Communication & Technology) business of Jujhar Group spearheaded by CMD S. Gurdeep Singh. The group has a legacy of over 30 years of business excellence. Jujhar Group of companies operates across verticals – Logistics, Hospitality, Real Estate, Digital entertainment, and next-generation services. More information, here: http://www.netplus.co.in/.
IP Infusion 소개
IP Infusion is a leading provider of open network software and solutions for carriers, service providers and data center operators with over 500 customers and thousands of deployments. Our solutions enable network operators to disaggregate their networks to accelerate innovation, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier grade robustness.
IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.
IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. Northforge Innovations is a registered trademark of Northforge Innovations, Inc. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.
미디어 문의
Katherine Verducci
1903 PR
kverducci@1903pr.com
408.429.5779
IP Infusion 소개
IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로서, 서비스 프로바이더, 데이터센터, AI 패브릭 네트워크를 위한 캐리어급 네트워크 운영체제인 OcNOS를 제공합니다. 26+ 년의 네트워킹 전문성과 전 세계 600+ 오퍼레이터 실적을 바탕으로, Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 오픈 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 완전 자회사입니다.
미디어 문의
For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.
미래예측 진술
본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.